The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
Open accessAbstract
Summary: Deferasirox is a once‐daily, oral iron chelator developed for treating transfusional iron overload. Preclinical studies indicated that the kidney was a potential target organ of toxicity. As patients with sickle cell disease often have abnormal baseline renal function, the primary objective of this randomised, open‐label, phase II trial was to evaluate the safety and tolerability of deferasirox in comparison with deferoxamine in this population. Assessment of efficacy, as measured by change in liver iron concentration (LIC) using biosusceptometry, was a secondary objective. A total of 195 adult and paediatric patients received deferasirox (n = 132) or deferoxamine (n = 63). Adverse events most commonly associated with deferasirox were mild, including transient nausea, vomiting, diarrhoea, abdominal pain and skin rash. Abnormal laboratory studies with deferasirox were occasionally associated with mild non‐progressive increases in serum creatinine and reversible elevations in liver function tests. Discontinuation rates from deferasirox (11·4%) and deferoxamine (11·1%) were similar. Over 1 year, similar dose‐dependent LIC reductions were observed with deferasirox and deferoxamine. Once‐daily oral deferasirox has acceptable tolerability and appears to have similar efficacy to deferoxamine in reducing iron burden in transfused patients with sickle cell disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866
Self-citationDams, R. O. J. A., Ie, V. I. C. M. C. K., Su, L. E. H., Iles, B. E. F., Ichinsky, E. L. V., Egelow, C. H. P., Bboud, M. I. A., Allagher, D. I. G., Utlar, K., Ichols, F. E. T. N., et al. (2015) · Cited by 1,338
(1989) · Medical Entomology and Zoology · Cited by 1,150
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
If Nothing Goes Wrong, Is Everything All Right?: Interpreting Zero Numerators
Hanley, J. A. (1983) · JAMA · doi:10.1001/jama.1983.03330370053031 · Cited by 1,043
Cappellini, M. D. (2006) · Blood · doi:10.1182/blood-2005-08-3430 · Cited by 717
Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa050460 · Cited by 635
Practical management of iron overload
Porter, J. B. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03195.x · Cited by 378
Self-citationResults of Long-Term Iron-Chelating Therapy
Gabutti, V., & Piga, A. (2009) · Acta Haematologica · doi:10.1159/000203853 · Cited by 378
Magnetic-Susceptibility Measurement of Human Iron Stores
Brittenham, G. M., Farrell, D. E., Harris, J. W., Feldman, E. S., Danish, E. H., Muir, W. A., Tripp, J. H., & Bellon, E. M. (1982) · New England Journal of Medicine · doi:10.1056/nejm198212303072703 · Cited by 367
Causes of death in sickle cell disease: an autopsy study
Manci, E. A., Culberson, D. E., Yang, Y., Gardner, T. M., Powell, R., Haynes, J., Shah, A. K., Mankad, V. N., & Investigators of the Cooperative Study of Sickle Cell Disease (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04594.x · Cited by 350
Brittenham, G. M., Cohen, A. R., McLaren, C. E., Martin, M. B., Griffith, P. M., Nienhuis, A. W., Young, N. S., Allen, C. J., Farrell, D. E., & Harris, J. W. (1993) · American Journal of Hematology · doi:10.1002/ajh.2830420116 · Cited by 270
Iron Overload Disorders: Natural History, Pathogenesis, Diagnosis, and Therapy
McLaren, G. D., Muir, W. A., Kellermeyer, R. W., & Jacobs, A. (1983) · CRC Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408368309165764 · Cited by 189
Fetus into man: physical growth from conception to maturity
Santos, R. V. (1993) · Cadernos de Saúde Pública · doi:10.1590/s0102-311x1993000500013 · Cited by 158
Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease
Ballas, S. K. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90058-7 · Cited by 153
Comparison of organ dysfunction in transfused patients with SCD or β thalassemia
Vichinsky, E. P., Butensky, E., Fung, E. B., Hudes, M. L., Theil, E. C., Ferrell, L. D., Williams, R., Louie, L. G., Lee, P., & Harmatz, P. (2005) · American Journal of Hematology · doi:10.1002/ajh.20402 · Cited by 137
Self-citationJensen, P. D. Ø., Jensen, F. T., Christensen, T., Nielsen, J. L., & Ellegaard, J. (2002) · Blood · doi:10.1182/blood-2002-06-1704 · Cited by 121
Effects of a long-term transfusion regimen on sickle cell-related illnesses
Styles, L. A., & Vichinsky, E. P. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)82006-2 · Cited by 92
Self-citationTransfusion Management in Sickle Cell Disease
Wanko, S. O., & Telen, M. J. (2005) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2005.07.002 · Cited by 75
Deferasirox—An Oral Agent for Chronic Iron Overload
VanOrden, H. E., & Hagemann, T. M. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g566 · Cited by 58
Barriers to adherence of deferoxamine usage in sickle cell disease
Treadwell, M. J., Law, A. W., Sung, J., Hackney-Stephens, E., Quirolo, K. C., Murray, E., Glendenning, G. A., & Vichinsky, E. P. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.20290 · Cited by 55
Self-citationDoes liver biopsy overestimate liver iron concentration?
Fischer, R., Harmatz, P., & Nielsen, P. (2006) · Blood · doi:10.1182/blood-2006-03-013482 · Cited by 17
Self-citationDoes liver biopsy overestimate liver iron concentration?
Fischer, R., Harmatz, P., & Nielsen, P. (2006) · Blood · doi:10.1182/blood-2006-03-009167 · Cited by 16
Self-citationMajor Changes in Sickle Cell Disease
Hagar, R. W., & Vichinsky, E. P. (2000) · Advances in Pediatrics · doi:10.1016/s0065-3101(23)00100-7 · Cited by 15
Self-citation
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Iron-Chelating Therapy for Transfusional Iron Overload
Brittenham, G. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmct1004810 · Cited by 366
Gujja, P., Rosing, D. R., Tripodi, D. J., & Shizukuda, Y. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.083 · Cited by 327
Cappellini, M. D., Porter, J., El-Beshlawy, A., Li, C. K., Seymour, J. F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J. W., Chan, L. L., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.014696 · Cited by 288
Self-citationAn update on iron chelation therapy.
(2012) · Europe PMC (PubMed Central) · doi:10.2450/2012.0008-12 · Cited by 233
Metadata
- Authors
- Vichinsky, E., Onyekwere, O., Porter, J., Swerdlow, P., Eckman, J., Lane, P., Files, B., Hassell, K., Kelly, P., Wilson, F., Bernaudin, F., Forni, G. L., Okpala, I., Ressayre‐Djaffer, C., Alberti, D., Holland, J., Marks, P., Fung, E., Fischer, R., Mueller, B. U., Coates, T., & the Deferasirox in Sickle Cell Investigators
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2006-12-21
- Volume
- 136
- Issue
- 3
- Pages
- 501-508
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1995812599
- Cited by
- 271
- References
- 24
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.